Cosmo Pharmaceuticals NV
SIX:COPN
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
36.5
79.9
|
Price Target |
|
We'll email you a reminder when the closing price reaches CHF.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one COPN stock under the Base Case scenario is 140.15 CHF. Compared to the current market price of 64 CHF, Cosmo Pharmaceuticals NV is Undervalued by 54%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Cosmo Pharmaceuticals NV
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for COPN cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Cosmo Pharmaceuticals NV
Balance Sheet Decomposition
Cosmo Pharmaceuticals NV
Current Assets | 183.6m |
Cash & Short-Term Investments | 133.4m |
Receivables | 36.3m |
Other Current Assets | 13.9m |
Non-Current Assets | 454.7m |
Long-Term Investments | 3.2m |
PP&E | 27.4m |
Intangibles | 398.5m |
Other Non-Current Assets | 25.7m |
Current Liabilities | 37.9m |
Accounts Payable | 14.7m |
Accrued Liabilities | 5.3m |
Other Current Liabilities | 18m |
Non-Current Liabilities | 101.9m |
Long-Term Debt | 714k |
Other Non-Current Liabilities | 101.2m |
Earnings Waterfall
Cosmo Pharmaceuticals NV
Revenue
|
189.3m
EUR
|
Cost of Revenue
|
-43.6m
EUR
|
Gross Profit
|
145.7m
EUR
|
Operating Expenses
|
-53.6m
EUR
|
Operating Income
|
92.1m
EUR
|
Other Expenses
|
-16.4m
EUR
|
Net Income
|
75.7m
EUR
|
Free Cash Flow Analysis
Cosmo Pharmaceuticals NV
EUR | |
Free Cash Flow | EUR |
COPN Profitability Score
Profitability Due Diligence
Cosmo Pharmaceuticals NV's profitability score is 69/100. The higher the profitability score, the more profitable the company is.
Score
Cosmo Pharmaceuticals NV's profitability score is 69/100. The higher the profitability score, the more profitable the company is.
COPN Solvency Score
Solvency Due Diligence
Cosmo Pharmaceuticals NV's solvency score is 99/100. The higher the solvency score, the more solvent the company is.
Score
Cosmo Pharmaceuticals NV's solvency score is 99/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
COPN Price Targets Summary
Cosmo Pharmaceuticals NV
According to Wall Street analysts, the average 1-year price target for COPN is 97.72 CHF with a low forecast of 79.79 CHF and a high forecast of 139.65 CHF.
Dividends
Current shareholder yield for COPN is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
COPN Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Cosmo Pharmaceuticals NV engages in the development, manufacturing, and distribution of treatments for gastrointestinal diseases, endoscopy, colorectal cancer diagnosis, and colonoscopy. The company is headquartered in Dublin, Dublin and currently employs 290 full-time employees. The company went IPO on 2016-05-18. The firm develops therapies for gastrointestinal disorders. The firm's clinical development pipeline specifically addresses treatments for inflammatory bowel diseases, colorectal cancer diagnosis and colonoscopy. The company has developed a medical device for polyp excision and is developing a product for the detection of colon cancer. Its pipeline includes Lialda/Mezavant/Mesavancol, which is indicated for mild to moderate ulcerative colitis; Uceris/Cortiment, which is indicated for mild to moderate ulcerative colitis; Zacol NMX, which is indicated for intestinal disorders; Rifamycin SV MMX, which is indicated for Travelers' Diarrhea and uncomplicated diverticulitis, among others; CB-17-01, which is indicated for chromoendoscopy for colorectal cancer prevention in surveillance patients; CB-17-04, which is a sub mucosal injectable composition, and CB-01-12, which is an antibody anti-tumor necrosis factor (TNF) alpha drug.
Contact
IPO
Employees
Officers
The intrinsic value of one COPN stock under the Base Case scenario is 140.15 CHF.
Compared to the current market price of 64 CHF, Cosmo Pharmaceuticals NV is Undervalued by 54%.